**CERTIFICATE OF ANALYSIS**

**CERTIFICATE No:**  CAN/2015-16/XYZ

|  |  |  |  |
| --- | --- | --- | --- |
| **PRODUCT** | LAMIVUDINE / ZIDOVIDNE TABLETS 150 mg/300 mg | | REF. NO: NDQD201508164 |
| **DATE RECEIVED:** 06.08.2015 | **LABEL CLAIM:** | Each film-coated tablet contains : Lamivudine U.S.P. 30 mg and Zidovudine U.S.P 60 mg. | |
| **BATCH NO.:** E132173A | **PRESENTATION:** | ?? | |
| **MGF. DATE:** Nov. 2013 | **MANUFACTURER:** | HETERO Labs Limited. | |
| **EXP. DATE:** Oct. 2016 | **ADDRESS:** | 22-110, i.d.a., Jeedimetla, Hyderabad-500 055, INDIA. | |
| **CLIENT REF NO:** | **CLIENT:** | National AIDS and STI Control Programme P.O. BOX 19361 Nairobi | |
|  | **TEST(S) REQUESTED:** | Uniformity of Weight, Identification, Dissolution, Assay | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **TEST** | **METHOD** | **COMPEDIA** | **SPECIFICATION** | **DETERMINED** | **REMARKS** |
| **Uniformity of Weight** | Weight | B.P. 2012 Vol. V App XII C | NMT 2 tablets deviate by more than 5% from mean weight | 1 Deviates (-7.7%) | **COMPLIES** |
| **Identification** | HPLC:HPLC | Adopted In-House Method | RT of the component peaks in the assay sample preparation correspond to that in the assay standard preparation | Super-imposable peaks at RT 2.8 and 3.7 Â± 10% min. present in both the assay sample and standard preparations | **COMPLIES** |
| **Dissolution** | HPLC:HPLC | Adopted In-House Method | No tablet less than 80.0% [n=6] | Lamivudine | **COMPLIES:COMPLIES** |
| **Dissolution** | HPLC:HPLC | Adopted In-House Method | No tablet less than 80.0% [n=6] | 90.3% (RSD = 1.8%; n = 6) | **COMPLIES:COMPLIES** |
| **Dissolution** | HPLC:HPLC | Adopted In-House Method | No tablet less than 80.0% [n=6] | Zidovudine | **COMPLIES:COMPLIES** |
| **Dissolution** | HPLC:HPLC | Adopted In-House Method | No tablet less than 80.0% [n=6] | 89.0% (RSD = 1.3%; n = 6) | **COMPLIES:COMPLIES** |
| **Assay** | HPLC:HPLC | Adopted In-House Method | 90.0 - 110.0% | Lamivudine | **COMPLIES:COMPLIES** |
| **Assay** | HPLC:HPLC | Adopted In-House Method | 90.0 - 110.0% | 97.1% (RSD = 0.4%; n = 12) | **COMPLIES:COMPLIES** |
| **Assay** | HPLC:HPLC | Adopted In-House Method | 90.0 - 110.0% | Zidovudine | **COMPLIES:COMPLIES** |
| **Assay** | HPLC:HPLC | Adopted In-House Method | 90.0 - 110.0% | 95.6% (RSD = 0.8%; n = 12) | **COMPLIES:COMPLIES** |

**CONCLUSION:** The product complies with the specifications for the tests performed.

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  | DATE: |
| DIRECTOR: | HEZEKIAH CHEPKWONY |  | DATE:11-05-2015 |